| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
The pathogenesis of recurrent miscarriage is poorly understood.
The blood coagulation-associated laboratory data of normal pregnant women demonstrated increased levels of thrombotic markers such as prothrombin fragment 1+2, thrombin-antithrombin complex, soluble fibrin and d-dimer. In BeWo cells, an in vitro model of the human placenta, TNF-α treatment enhanced expression of procoagulant proteins including tissue factor and plasminogen activator inhibitor-1 (PAI-1). Meanwhile, fluvastatin enhanced expression of anticoagulant proteins including tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin type 1 repeats (ADAMTS13) in human umbilical vein endothelial cells.
Those results indicate that pregnant women are at higher risk of thrombosis, which is accelerated by inflammation in some cases of adverse pregnancy outcome. Fluvastatin may improve antithrombotic properties of endothelium and attenuate thrombotic tendencies during pregnancy.
|
